Mgi Pharma Inc

Mgi Pharma — UBS Global Life Sciences Conference 2004

24 slides from Mgi Pharma's conference presentation, Oct 1, 2004

  1. Slide 1: MGI PHARMA presentation at UBS Global Life Sciences Conference

    MGI PHARMA, Presented Global September MAKING Lifeat A27, Sciences the REAL 2004 UBS INC. DIFFERENCE Conference IN THE LIVES OF CANCER PATEINTS

  2. Slide 2: Forward-Looking Statements

    Forward-Looking This MAKING presentation A REAL contains Statements DIFFERENCE forward- IN looking THE statements LIVES OF that CANCER involvePATEINTS risks and uncertainties, including those described in the Company’s Securities and Exchange Commission filings.

  3. Slide 3: Mission & Strategy

    MGIacquire, We MAKING PHARMAAdevelop REAL Mission is anDIFFERENCE and oncology- commercialize & Strategy focused IN THE proprietary biopharmaceutical LIVES OFpharmaceutical CANCER companyPATEINTS products that address patient needs

  4. Slide 4: Recently completed transactions

    MGI PHARMA Licensed Acquiring Acquired Expanded MAKING WW Zycos, oncology Aloxi® Aesgen, A REAL rights Recently a rights privately apromotion DIFFERENCE privately to Dacogen™ tocompleted include held held rights company company postoperative (decitabine) INfor transactions THE Kadian® focused LIVES

  5. Slide 5: Successful efforts and financings

    MGI PHARMA Successful ~20% Completed Raised Positioned Focused Therapeutics: Supportive MAKING market $169M efforts A Aloxi MGI two care: REAL share Dacogen, in financings on PHARMA Creating Kadian, injection follow acquiring DIFFERENCE ZYC101a on Saforis™ alaunch leading to and product add $252M in

  6. Slide 6: Product portfolio

    MGI PHARMA Salagen® Hexalen® Kadian® Dacogen™ Saforis™ ZYC101a ZYC300 Aloxi® Combination Monotherapy Irofulven Other MG98 Preclinical MAKINGAcylfulvene Injection oral (solid Capsules (oral Tablets (cervical A Capsules Phase (MDS) formulation REAL Therapy mucositis) tumors) Product (CINV) (PONV) 1Ana

  7. Slide 7: Aloxi Injection

    AloxiTM The Approved Favorable Strong Long Extended Exclusive Approx. MAKING Best-In-Class half binding 20% activity Injection life U.S. head-to-head for A REAL CINV both & affinity Canadian 5-HT3 acute DIFFERENCE market (potency) trials and antagonist CINV share delayed compared in rights IN July f

  8. Slide 8: Cancer supportive care market (5-HT3 injection)

    AloxiTM Cancer 2003 2002 2001 2000 1999 $1,800,000 $1,600,000 $1,400,000 $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $0 Includes PONV/other MAKING market all Injection Aindications, REALU.S. DIFFERENCE both 5-HT3I.V.cancer and INoral market THE formulations. LIVES approaching OF CANCER

  9. Slide 9: Aloxi monthly units launch success

    Aloxi® Monthly 0 (000’s) 1 Launch MAKING Aloxi Anzemet Kytril Zofran 220340 4 5Month 60 Launch IV 6A80 7Units REAL 8100 9 Success 10(CINV) 120 11 DIFFERENCE 12 140 Initial Reported 12 months IN byTHE IMSforLIVES each 5HT3 OF CANCER antagonistPATEINTS

  10. Slide 10: Product portfolio

    MGI PHARMA Salagen® Hexalen® Kadian® Dacogen™ Saforis™ ZYC101a ZYC300 Aloxi® Combination Monotherapy Irofulven Other MG98 Preclinical MAKINGAcylfulvene Injection oral (solid Capsules (oral Tablets (cervical A Capsules Phase (MDS) formulation REAL Therapy mucositis) tumors) Product (CINV) (PONV) 1Ana

  11. Slide 11: Kadian

    Kadian® 3 Indicated Oncology Promotion Excellent MAKING year promotion Morphine for fit launch Arevenue with REAL management by agreement our will DIFFERENCE sulfate MGI oncology bePHARMA of used sustained from moderate supportive toAlpharma help INrelease inTHE to offset September severe care LIVES

  12. Slide 12: Product portfolio

    MGI PHARMA Salagen® Hexalen® Kadian® Dacogen™ Saforis™ ZYC101a ZYC300 Aloxi® Combination Monotherapy Irofulven Other MG98 Preclinical MAKINGAcylfulvene Injection oral (solid Capsules (oral Tablets (cervical A Capsules Phase (MDS) formulation REAL Therapy mucositis) tumors) Product (CINV) (PONV) 1Ana

  13. Slide 13: Dacogen

    Dacogen™ WW $40M $15M 20% NDA Potential Phase Leverages MAKING to licensing and 3committed equity 30% AML trial utility MAA A MGI Anti-cancer in royalty REAL investment, trial agreement MDS in PHARMA’s submissions development MDS, projected DIFFERENCE tocomplete SuperGen agent AML, $45M with to core

  14. Slide 14: Product portfolio

    MGI PHARMA Salagen® Hexalen® Kadian® Dacogen™ Saforis™ ZYC101a ZYC300 Aloxi® Combination Monotherapy Irofulven Other MG98 Preclinical MAKINGAcylfulvene Injection oral (solid Capsules (oral Tablets (cervical A Capsules Phase (MDS) formulation REAL Therapy mucositis) tumors) Product (CINV) (PONV) 1Ana

  15. Slide 15: Saforis

    Saforis™ To $32M 5% Proprietary One Primary Significant Second Builds MAKING be royalty phase obtained in on phase endpoint cash Phase MGI A 3activity on formulation trial REAL plus 3sales through PHARMA’s trial 3complete met candidate milestone in DIFFERENCE to expected prevention (p=0.026): Aesgen

  16. Slide 16: Product portfolio

    MGI PHARMA Salagen® Hexalen® Kadian® Dacogen™ Saforis™ ZYC101a ZYC300 Aloxi® Combination Monotherapy Irofulven Other MG98 Preclinical MAKINGAcylfulvene Injection oral (solid Capsules (oral Tablets (cervical A Capsules Phase (MDS) formulation REAL Therapy mucositis) tumors) Product (CINV) (PONV) 1Ana

  17. Slide 17: ZYC101a

    ZYC101a Obtained $50M Immune In Overall, Phase Target MAKING a prospectively 32cash gynecologist study pivotal 43% response through Immunotherapeutic Atransaction REAL resolution completed program acquisition therapeutic defined DIFFERENCE audience for expected inpopulation 161 ZYC101a of overlaps f

  18. Slide 18: Product portfolio

    MGI PHARMA Salagen® Hexalen® Kadian® Dacogen™ Saforis™ ZYC101a ZYC300 Aloxi® Combination Monotherapy Irofulven Other MG98 Preclinical MAKINGAcylfulvene Injection oral (solid Capsules (oral Tablets (cervical A Capsules Phase (MDS) formulation REAL Therapy mucositis) tumors) Product (CINV) (PONV) 1Ana

  19. Slide 19: Irofulven

    A novel, Irofulven New Novel Activity Monotherapy Combination Strong HRPC MAKINGchemotherapeutic mechanism combination patent independent broadly A REAL activity position activity active ofDIFFERENCE trial action of in in and class cytotoxic P53 prostate, prostate, underway exclusive and bcl-2 color

  20. Slide 20: FY 04 Financial Guidance

    FY R&D Aloxi Other Licensing Cost SG&A R&D Q3 Loss MAKING 2004 of before expenses product injection expenses product Financial isrevenue Aexpected interest REAL sales sales of sales ofapprox. of Guidance approximately of DIFFERENCE &of to as approximately approx. taxes $140 be a percent $40 approxim

  21. Slide 21: FY 2005 Financial Guidance

    FY 2005 Total EBIT Product MAKINGrevenues operating of candidates $75 Financial A REAL million of expenses approx. Guidance acquired DIFFERENCE of $280 $205 and Asmillion provided announced million IN THESeptember on LIVES September OF 1, 2004 CANCER 1, 2004 PATIENTS could add $500 million in combin

  22. Slide 22: Balance Sheet

    Balance June Cash Long-term Total Shares *Excludes 75,944 $197,750 $260,172 $488,697 $412,063 Actual MAKING30, Assets and Shareholders’ Outstanding, Sheet 2004 Marketable A approx. Debt REAL (in thousands) 8.27 Equity DIFFERENCE Fully Investments million Diluted* shares IN that THEcould LIVES be OF

  23. Slide 23: Focused Execution

    MGI PHARMA Maximize Leverage Advance Aloxi MAKING Irofulven ZYC101a Saforis Dacogeninjection oral the sales commercial A formulation REAL development force for Focused PONV DIFFERENCE bypotential launching Execution of clinical of in-licensed, Aloxi INproduct THE injection LIVES candidates, acquired

  24. Slide 24: Building a Leading Oncology-Focused Biopharmaceutical Company

    MGI PHARMA, Building Biopharmaceutical MAKING aA Leading REALINC. Company Oncology-Focused DIFFERENCE IN THE LIVES OF CANCER PATIENTS

MGI Pharma — UBS Global Life Sciences Conference 2004 on 6ix